- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06009874
Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI
Clinical Investigation of Cardioprotective Effect of Early Administration of Sodium-glucose Cotransport-2 Inhibitors in Patients With Acute Myocardial Infarction
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
DAPA was approved for HF patients, but there is no sufficient data about its efficacy on patients with AMI and if it can protect from the development of HF after AMI.
the investigators aim to investigate the effect of DAPA on patients who presented with AMI when administered as early as possible before pPCI and to be continued for three months after there.
the effect of DAPA on infarct size, cardiac biomarkers will be assessed during the follow-up period
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mohammad Soliman
- Phone Number: +201003474565
- Email: dr.mhtantawy@gmail.com
Study Locations
-
-
Menofia
-
Shibīn Al Kawm, Menofia, Egypt, 32741
- Recruiting
- Mohammad Soliman
-
Contact:
- Mohammad Soliman
- Email: dr.mhtantawy@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with ST-elevation myocardial infarction (STEMI).
- STEMI was defined according to the Fourth Universal Definition of AMI.
- 18 - 80 years of age.
- Diabetics or non-diabetics.
- eGFR > 45 ml/min/1.73m2.
- Blood pressure before first drug dosing >110/70 mmHg.
Exclusion Criteria:
- Cardiogenic shock.
- Hypoglycemia.
- History of diabetic ketoacidosis.
- Genital and urinary infections.
- History of AMI.
- Stent thrombosis.
- Previous coronary artery bypass surgery.
- Severe hepatic insufficiency.
- Advanced cancer patients.
- Blood pH < 7.32.
- Known allergy to SGLT-2 inhibitors.
- Hemodynamic instability.
- Females of childbearing potential without adequate contraceptive methods.
- Patients currently on or have received any SGLT-2 inhibitors.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Dapagliflozin group
patients with MI will be treated with DAPA 10 mg once daily for three months.
|
patients will be treated with DAPA 10 mg once daily for three months
Other Names:
|
Placebo Comparator: Placebo group
patients with MI will be treated with a matching placebo once daily for three months.
|
patients will be treated with a placebo tab once daily for three months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
difference in infarct size
Time Frame: 3 months
|
infarct size measurement (percentage) for both groups
|
3 months
|
difference in NT-proBNP level
Time Frame: 3 months
|
NT-proBNP level (pg/ml) for both groups
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in eGFR
Time Frame: 3 months
|
Decline in eGFR (ml/min) for both groups
|
3 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Myocardial Infarction
- Infarction
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Sodium-Glucose Transporter 2 Inhibitors
- Dapagliflozin
Other Study ID Numbers
- 35541/6/22
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Infarction
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Hvidovre University... and other collaboratorsRecruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationActive, not recruitingST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionCanada
-
Karolinska InstitutetUppsala University; The Swedish Research CouncilActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionSweden
-
Oslo University HospitalVestre Viken Hospital Trust; University of Oslo; University Hospital of North... and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionNorway
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
Clinical Trials on Dapagliflozin 10mg Tab
-
Chinese University of Hong KongRecruitingChronic Hepatitis BHong Kong
-
Seoul National University Bundang HospitalRecruitingDiabetes Type 2Korea, Republic of
-
Fondazione IRCCS Policlinico San Matteo di PaviaRecruiting
-
Region Örebro CountyLondon School of Hygiene and Tropical Medicine; Odense University Hospital; Göteborg... and other collaboratorsRecruitingAtrial Fibrillation | Chronic Coronary SyndromeDenmark, Sweden, Czechia
-
Nidae AlaaRecruitingDiabetic RetinopathyEgypt
-
Oman Ministry of HealthNot yet recruitingObesity | Weight Loss | Effect of Drug | Dapagliflozin Adverse Reaction
-
Nanjing University School of MedicineRecruiting
-
Monaldi HospitalRecruitingEfficacy | Systemic Right Ventricle | Dapagliflozin Adverse ReactionItaly
-
Albert Einstein Healthcare NetworkSuspendedAcute Kidney Injury | Percutaneous Coronary InterventionUnited States